488 related articles for article (PubMed ID: 14747041)
1. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer.
Gomella LG; Zeltser I; Valicenti RK
Urology; 2003 Dec; 62 Suppl 1():46-54. PubMed ID: 14747041
[TBL] [Abstract][Full Text] [Related]
2. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer.
Pisansky TM
Urology; 2003 Dec; 62 Suppl 1():36-45. PubMed ID: 14747040
[TBL] [Abstract][Full Text] [Related]
3. Hormone therapy in advanced prostate cancer.
Forster TH; Stoffel F; Gasser TC
Front Radiat Ther Oncol; 2002; 36():49-65. PubMed ID: 11842755
[No Abstract] [Full Text] [Related]
4. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
[TBL] [Abstract][Full Text] [Related]
5. [Combination of external irradiation and androgen suppression for prostate cancer: facts and questions].
Bolla M; Fourneret P; Beneyton V; Tessier A; Jover F; Verry C
Cancer Radiother; 2010 Oct; 14(6-7):510-4. PubMed ID: 20728391
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer.
Cannon GM; Walsh PC; Partin AW; Pound CR
Urology; 2003 Dec; 62 Suppl 1():2-8. PubMed ID: 14747037
[TBL] [Abstract][Full Text] [Related]
7. [Therapy of nodal positive prostatic carcinoma: when should hormone therapy be started?].
Zierhut D
Strahlenther Onkol; 1998 Jul; 174(7):382-3. PubMed ID: 9689961
[No Abstract] [Full Text] [Related]
8. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
10. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
Pienta KJ;
Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
[TBL] [Abstract][Full Text] [Related]
11. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
Ryan CJ; Small EJ
Urology; 2003 Dec; 62 Suppl 1():87-94. PubMed ID: 14747046
[TBL] [Abstract][Full Text] [Related]
12. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
13. [Place of surgery in high-risk tumours of the prostate].
Soulié M; Rozet F; Hennequin C; Salomon L;
Cancer Radiother; 2010 Oct; 14(6-7):493-9. PubMed ID: 20727805
[TBL] [Abstract][Full Text] [Related]
14. [Hormono-radiotherapy of non-metastatic prostate cancers].
Richaud P; Mazeron JJ
Cancer Radiother; 2002 May; 6(3):175-82. PubMed ID: 12116843
[TBL] [Abstract][Full Text] [Related]
15. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
Cher ML; Shinohara K; Breslin S; Vapnek J; Carroll PR
Br J Urol; 1995 Jun; 75(6):771-7. PubMed ID: 7542137
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints.
Oh WK
Urol Oncol; 2003; 21(3):229-34. PubMed ID: 12810211
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy.
Andriole GL
Eur Urol; 1997; 32 Suppl 3():65-9. PubMed ID: 9267788
[TBL] [Abstract][Full Text] [Related]
18. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
Koontz BF; Lee WR
Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer.
Lam ET; Glodé LM
Hematol Oncol Clin North Am; 2013 Dec; 27(6):1189-204, viii. PubMed ID: 24188258
[TBL] [Abstract][Full Text] [Related]
20. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
